Supplemental Material

Humidity and deposition solution play a critical role in virus inactivation by heat treatment on N95 respirators

Nicole Rockey,^a* Peter J. Arts,^a* Lucinda Li,^a* Katherine R. Harrison,^a Kathryn Langenfeld,^a William J. Fitzsimmons,^b Adam S. Lauring,^b Nancy G. Love,^a Keith S. Kaye,^b Lutgarde Raskin,^a William W. Roberts,^{c,d} Bridget Hegarty,^a Krista R. Wigginton^{a#}

^aDepartment of Civil & Environmental Engineering, University of Michigan, Ann Arbor, MI, USA

^bDivision of Infectious Diseases, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA

^cDepartment of Urology, University of Michigan Health System, Ann Arbor, MI, USA

^dDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA

#Address correspondence to Krista R. Wigginton, kwigg@umich.edu, 734-763-9664

*Authors contributed equally to this work.

Control experiment to test the potential impact of drying time. The MS2 and phi6 virus stock was deposited on coupons and allowed to dry for either one or three hours prior to the heat treatment. The results from this control experiment confirmed that the log₁₀ inactivation observed through heat treatment was not affected by the drying time of virus droplets on the coupon (Figure S1).

Virus recovery from N95 respirator coupons. To assess virus recovery from N95 respirator coupons, 50 uL of each of the virus stocks was suspended into their respective elution solutions. The virus suspensions were extracted and enumerated with the same methods used on the coupons. Recovery rates were calculated as the ratio of the control coupon titer to the virus suspension. Average recovery rates for each virus tested are 56% for IAV, 28% for MHV, 38% for MS2 suspended in PBS, 34% for MS2 suspended in IAV media, 104% for phi6 suspended in PBS, and 7% for phi6 suspended in IAV media.

Virus	Genome type	Genome size	Particle size (nm)	Enveloped/ Nonenveloped
SARS-CoV-2	(+)ssRNA	29.9 kb	~100	Enveloped
MS2	(+)ssRNA	3.6 kb	~25	Nonenveloped
phi6	dsRNA	13.5 kbp	~85	Enveloped
IAV	(-)ssRNA	13.6 kb	~100	Enveloped
MHV	(+)ssRNA	31.3 kb	~120	Enveloped

 Table S1. Characteristics of SARS-CoV-2 and the viruses used in this study.

Matrix	Description							
IAV medium	DMEM supplemented with 0.1875% Fraction V BSA, 25 mM HEPES, and % antibiotics (Table S2)							
MHV medium	DMEM supplemented with 2% horse serum, L-glutamine, and 1% antibiotics (Table S2)							
PBS	1X phosphate buffered saline (Table S3)							
PBS + BSA	1X phosphate buffered saline (Invitrogen) supplemented with 0.1875% Fraction V BSA							
Saliva	UV sterilized fresh saliva collected from human volunteers							

 Table S2. Deposition solutions used in experiments.

tor depositing viruses, us stated by the manarateurer.									
Component	Туре	Concentration							
Potassium Chloride (KCl)	Inorganic Salt	2.7 mM							
Potassium Phosphate (NaH ₂ PO ₄)	Inorganic Salt	1.8 mM							
Sodium Chloride (NaCl)	Inorganic Salt	137 mM							
Sodium Phosphate (NaH ₂ PO ₄)	Inorganic Salt	10 mM							

Table S3. Composition of phosphate buffer saline solution (Invitrogen, Cat. No. 10010023) used for depositing viruses, as stated by the manufacturer.

Component	Туре	IAV medium	MHV medium	
DMEM		·		
Glycine	Amino Acid	0.4 mM	0.4 mM	
L-Arginine hydrochloride	Amino Acid	0.4 mM	0.4 mM	
L-Cystine 2HCl	Amino Acid	0.2 mM	0.2 mM	
L-Glutamine	Amino Acid	4 mM	2 mM*	
L-Histidine hydrochloride-H ₂ O	Amino Acid	0.2 mM	0.2 mM	
L-Isoleucine	Amino Acid	0.8 mM	0.8 mM	
L-Leucine	Amino Acid	0.8 mM	0.8 mM	
L-Lysine hydrochloride	Amino Acid	0.8 mM	0.8 mM	
L-Methionine	Amino Acid	0.2 mM	0.2 mM	
L-Phenylalanine	Amino Acid	0.4 mM	0.4 mM	
L-Serine	Amino Acid	0.4 mM	0.4 mM	
L-Threonine	Amino Acid	0.8 mM	0.8 mM	
L-Tryptophan	Amino Acid	0.08 mM	0.08 mM	
L-Tyrosine disodium salt dihydrate	Amino Acid	0.4 mM	0.4 mM	
L-Valine	Amino Acid	0.8 mM	0.8 mM	
Choline chloride	Vitamin	0.03 mM	0.03 mM	
D-Calcium pantothenate	Vitamin	0.01 mM	0.008 mM	
Folic acid	Vitamin	0.01 mM	0.009 mM	
i-Inositol	Vitamin	0.04 mM	0.04 mM	
Niacinamide	Vitamin	0.03 mM	0.03 mM	
Pyridoxine hydrochloride	Vitamin	0.02 mM	0.02 mM	
Riboflavin	Vitamin	0.001 mM	0.001 mM	
Thiamine hydrochloride	Vitamin	0.01 mM	0.01 mM	
Calcium Chloride (CaCl ₂) (anhyd.)	Inorganic Salt	1.8 mM	1.8 mM	

Table S4. Composition of IAV and MHV media used for deposition solutions.

Ferric Nitrate (Fe(NO ₃) ₃ - 9H ₂ O)	Inorganic Salt	0.0002 mM	0.0002 mM
Magnesium Sulfate (MgSO ₄) (anhyd.)	Inorganic Salt	0.8 mM	0.8 mM
Potassium Chloride (KCl)	Inorganic Salt	5.3 mM	5.4 mM
Sodium Bicarbonate (NaHCO ₃)	Inorganic Salt	44 mM	44 mM
Sodium Chloride (NaCl)	Inorganic Salt	110.3 mM	109.5 mM
Sodium Phosphate monobasic (NaH ₂ PO ₄ - H ₂ O)	Inorganic Salt	0.9 mM	0.9 mM
D-Glucose (Dextrose)	Other	25 mM	25 mM
Phenol red	Other	0.04 mM	0.04 mM
HEPES (N-2- hydroxyethylpiperazine-N-2- ethane sulfonic acid)	Organic chemical	25 mM	-
Bovine serum albumin (Fraction V)	Protein	0.1875%	-
Horse serum	Protein	-	2%
Penicillin/Streptomycin	Antibiotics	1%	1%

*Not in DMEM, added separately.

Table S5. Relative humidity readings from the external instantaneous hygrometer probe for each humidity and temperature controlled oven relative humidity setting. Values were measured in duplicate at 20 minute intervals as the humidity setting was increased and decreased. Average probe measurement is reported with the range of readings in parentheses.

Relative	Temperature Setting, °C						
Setting, %	72	82					
10	0.82 (0.55, 1.08)	0.61 (0.53, 0.68)					
20	13.18 (12.72, 13.63)	13.17 (12.48, 13.85)					
30	24.48 (24.42, 24.54)	24.76 (24.31, 25.20)					
40	36.06 (36.02, 36.10)	35.89 (35.53, 36.25)					
50	48.19 (48.12, 48.25)	48.39 (48.33, 48.45)					
70	70.42 (70.19, 70.65)	71.12 (70.03, 72.21)					
90	88.52 (86.02, 91.02)	90.16 (89.88, 90.43)					

Temperature			$72^{\circ}C^{a}$						82°C ^a								
Deposition solution		PBS		IAV Medium		Saliva		PBS -	⊦ BSA	A PBS		IAV Medium		Saliva		PBS + BSA	
	1	0.11	0.36	1.31	1.57					0.08	0.29	2.42	3.12	0.73	1.02	0.90	0.64
	1	(0.24)		(1.44)		-	-		-		19)	(2.	77)	(0.	88)	(0.'	77)
	13	0.41	0.34	5.02	4.75	1.01	0.96	1.53	1.46	1.36	0.96	5.54	> 6.35	1.44	2.03	3.28	3.64
	15	(0.38) (4.89)		89)	(0.99)		(1	.5)	(1.	16)	(5.	93)	(1.	74)	(3.4	46)	
dity (%	25	1.31	1.46	6.41	6.28	1.41	1.48	2.25	3.18	4.07	4.03	> 6.86	> 6.18				
	25	(1.3	(1.39) (6.35)		(1.4	5)	(2.72)		(4.05)		(> 6.52)		-		-		
mic	26	3.71	3.72	> 6.67	> 6.74					> 6.71	6.03	> 6.80	> 6.75				
e hu	50	(3.7	(3.72) (> 6.71)		-		-		(> 6.37)		(> 6.78)		-		-		
ıtive	18	> 6.81	6.64	> 6.57	> 6.19					> 6.78	> 6.32	> 6.58	> 5.48				
Rela	40	(> 6	.73)	(> 6	.38)	-			-	(>6	(> 6.55)		5.03)		-	-	
—	71	> 6.85	> 6.62	> 6.86	> 6.43					> 6.58	> 7.09	> 6.83	> 7.13				
	/1	(> 6	.74)	(> 6	.65)	-			-	(> 6	5.84)	(>6	5.98)		-	-	•
	80	> 7.11	> 6.62	> 6.93	> 6.19					> 6.83	> 6.96	>6.99	> 7.33				
	09	(> 6	.87)	(> 6	.56)	-			-	(> 6	5.90)	(> 7	7.16)		-	-	

Table S6. Log₁₀ inactivation of bacteriophage MS2 across variable heat and humidity treatments and deposition solutions.

^aReplicates shown side-by-side for a given treatment, and arithmetic mean shown in parentheses below replicates. Greater than symbol is used to designate replicates outside of dynamic range. For treatment settings with one or more replicates outside of dynamic range, the arithmetic mean was calculated from the values shown.

Temperature					72°C ^a					82°C ^a							
Deposition solution		PBS IAV Medium		Saliva PBS + BSA		PBS		IAV Medium		Saliva		PBS + BSA					
	1	0.85	1.12	2.77	2.38					0.79	2.16	3.08	4.66	1.11	1.06	1.07	0.44
	1	(0.99)		(2.58)			-		(1.	(1.48)		(3.87)		09)	(0.7	76)	
	12	1.97	1.27	4.48	4.12	1.19	0.70	1.26	1.40	3.84	2.97	6.61	7.18	2.33	2.91	2.44	1.51
(15	(1.62) (4.3)		(0.9	(0.95) (1.33)		(3.41)		(6.9)		(2.62)		(1.98)				
dity (%	25	3.07	2.63	6.02	> 7.44	1.78	1.60	1.11	1.56	5.60	5.38	>8.08	> 7.18				
	25	(2.8	35)	(> 6	5.73)	(1.6	9)	(1.34)		(5.49)		(> 7.63)		-		-	
mic	26	4.88	5.65	> 7.70	> 7.41					> 7.25	> 6.30	> 7.40	> 6.38				
hu	30	(5.2	27)	(> 7.56)		-		-		(> 6.78)		(> 6.89)		-		-	
tive	40	7.14	7.03	> 7.76	> 7.45					> 6.97	>6.49	> 7.55	> 5.95				
Rela	48	(7.0)9)	(> 7	.61)	-		-		(> 6.73)		(> 6.75)		-		-	•
H	71	> 6.20	> 7.05	> 7.83	> 7.10					> 7.08	> 7.02	> 7.40	> 7.54				
	/1	(> 6.	63)	(> 7	.47)	-		-	-	(> 7	7.05)	(> 7	7.47)	-	-	-	•
	00	> 6.86	> 6.72	> 7.62	> 6.00				> 7.07	> 6.33	> 7.74	4 > 7.51					
	89	(> 6.	.79)	(> 6	.81)	-		-	-	(>6	5.70)	(> 7	7.63)		•	-	•

Table S7. Log_{10} inactivation of bacteriophage phi6 across variable heat and humidity treatments and deposition solutions.

^aReplicates shown side-by-side for a given treatment, and arithmetic mean shown in parentheses below replicates. Greater than symbol is used to designate replicates outside of dynamic range. For treatment settings with one or more replicates outside of dynamic range, the arithmetic mean was calculated from the values shown.

Temperature		72°	${}^{\mathbf{p}}\mathbf{C}^{\mathbf{a}}$	82°C ^a		
	1	2.56	2.45	3.85	2.75	
Relative humidity (%	1	(2.:	51)	(3.30)		
	13	3.98	3.50	> 3.96	4.14	
		(3.1	74)	(> 4.05)		
	25	3.61	> 4.05	> 3.89	> 4.49	
	23	(> 3	.83)	(>4	1.19)	
	80	> 4.19	> 4.19	> 4.33	> 4.43	
	09	(>4	.19)	(>4	.38)	

Table S8. Log₁₀ inactivation of IAV across variable heat and humidity treatments.

^aReplicates shown side-by-side for a given treatment, and arithmetic mean shown in parentheses below replicates. Greater than symbol is used to designate replicates outside of dynamic range. For treatment settings with one or more replicates outside of dynamic range, the arithmetic mean was calculated from the values shown.

Temper	rature	72	°C ^a	82°C ^a			
	1	0.89	1.60	2.89	2.53		
	1	(1.	25)	(2.71)			
%				>	>		
ity	13	2.56	2.48	4.17	3.45		
nid		(2.	52)	(> 3.81)			
Inc		>	>	>	>		
ve l	25	3.52	3.59	3.56	3.31		
ati		(> 3	5.56)	(> 3	5.44)		
Rel		>	>	>	>		
	89	3.83	3.59	3.30	3.43		
		(> 3	5.71)	(> 3	5.37)		

Table S9. Log₁₀ inactivation of MHV across variable heat and humidity treatments.

^aReplicates shown side-by-side for a given treatment, and arithmetic mean shown in parentheses below replicates. Greater than symbol is used to designate replicates outside of dynamic range. For treatment settings with one or more replicates outside of dynamic range, the arithmetic mean was calculated from the values shown.

	Treat	Treatment					
Virus	Deposition Solution	RH (%)	82°C				
		1	0.306				
		1	(0.79)				
	DDC	13	3.87				
	1 05	15	(0.061)				
		25	34.3				
MS2		23	(0.0008)				
11152	IAV	1	3.56				
	Medium	1	(0.071)				
	Saliya	13	2.53				
	Sanva	15	(0.13)				
	PBS + BSA	13	10.7				
	105 1051	15	(0.0086)				
		1	0.702				
		1	(0.56)				
	PRS	13	3.20				
	1 05	15	(0.086)				
		25	10.73				
		25	(0.0086)				
nhi6		1	1.59				
ршо	IAV	1	(0.25)				
	Medium	13	7.79				
		15	(0.017)				
	Saliva	13	4.41				
	Sanva	10	(0.048)				
	PRS + RSA	13	1.37				
		15	(0.30)				
IAV	IAV	1	1.44				
14 2 4	Medium	4	(0.29)				
MHV	MHV	1	3.68				
TATT A	Medium	1	(0.067)				

 Table S10. Results of unpaired t-tests comparing virus log₁₀-inactivation values at 72°C and 82°C.

			t-test (p-value) ^a					
Temperature (°C)	Virus	Matrix	1% versus 13% RH	13% versus 25% RH	25% versus 36% RH	36% versus 48% RH		
	MS2	PBS	1.08 (0.39)	1.0812.2(0.39)(0.0066)		NA		
	IVI52	IAV Medium	18.38 (0.0029)	9.74 (0.010)	NA	NA		
72		PBS	1.69 (0.23)	2.98 (0.10)	5.45 (0.032)	4.68 (0.043)		
72	рпю	IAV Medium	6.50 (0.023)	NA	NA	NA		
	IAV	IAV Medium	5.02 (0.038)	NA	NA	NA		
	MHV	MHV Medium	3.57 (0.070)	NA	NA	NA		
	MS2	PBS	4.32 (0.050)	14.4 (0.0048)	NA	NA		
87	14132	IAV Medium	5.93 (0.027)	NA	NA	NA		
82	nhi6	PBS	2.38 (0.14)	4.65 (0.043)	NA	NA		
	рпю	IAV Medium	3.60 (0.069)	NA	NA	NA		

Table S11. Results of unpaired t-tests comparing virus inactivation at different RHs.

NA = Not assessed, because values were below detection limits.

Treatment		t-test (p-value) ^a					
Temperature (°C)	RH (%)	MS2 versus phi6	MS2 versus IAV	MS2 versus MHV	phi6 versus IAV	phi6 versus MHV	IAV versus MHV
72	1	4.84	7.55	0.52	0.346	3.28	3.51
		(0.040)	(0.017)	(0.66)	(0.76)	(0.082)	(0.073)
	13	2.60	4.16	16.8	1.87	9.65	5.01
		(0.12)	(0.053)	(0.0035)	(0.20)	(0.011)	(0.038)
82	1	1.27	0.813	0.152	0.592	1.43	1.02
		(0.33)	(0.50)	(0.89)	(0.61)	(0.29)	(0.42)

Table S12. Results of unpaired t-tests comparing virus log₁₀ inactivation for viruses in tissue culture media deposition solution.

Temperature (°C)	Virus	RH (%)	t-test (p-value) ^a					
			PBS versus saliva	PBS versus PBS+BSA	PBS versus IAV medium	IAV medium versus saliva	IAV medium versus PBS+BSA	
72	MS2	1	NA	NA	6.68 (0.022)	NA	NA	
		13	14.2 (0.0049)	22.6 (0.0019)	32.3 (0.0010)	28.4 (0.0012)	24.3 (0.0017)	
		25	0.725 (0.54)	2.82 (0.11)	50.0 (0.0004)	66.40 (0.0002)	7.73 (0.016)	
	phi6	1	NA	NA	6.70 (0.022)	NA	NA	
		13	1.58 (0.25)	0.81 (0.50)	6.81 (0.021)	11.0 (0.0081)	15.4 (0.0042)	
		25	4.88 (0.040)	4.81 (0.041)	NA	NA	NA	
82	MS2	1	3.85 (0.061)	3.50 (0.073)	7.07 (0.019)	5.00 (0.038)	5.36 (0.033)	
		13	1.61 (0.25)	8.55 (0.013)	NA	NA	NA	
	phi6	1	0.569 (0.63)	0.955 (0.44)	2.29 (0.15)	3.52 (0.072)	3.66 (0.067)	
		13	1.50 (0.27)	2.25 (0.15)	6.71 (0.021)	10.5 (0.0089)	9.02 (0.012)	

Table S13. Results of unpaired t-tests comparing virus inactivation for an expanded set of deposition solutions.

	t-test (p-value) ^a		
Temperature (°C)	Deposition Solution	RH (%)	MS2 versus phi6
		1	4.08
		I	(0.055)
	PBS	13	3.54
			(0.071)
		25	6.30
			(0.024)
	IAV Medium	36	4.03
			(0.057)
		1	4.84
72			(0.040)
		13	2.60
			(0.12)
		13	0.162
	Saliva		(0.89)
		25	2.54
			(0.13)
		13	2.1
	PBS + BSA		(0.17)
		25	2.7
			(0.12)
		1	4.68
			(0.043)
	PBS	13	1.14
		25	(0.37)
			5.45 (0.022)
			(0.032)
	IAV Medium	1	(0.33)
82		1	1.43
			(0.29)
	Saliva		2 14
		13	(0.17)
	PBS + BSA	1	0.0440
			(0.97)
			2.98
		13	(0.10)

Table S14. Results of unpaired t-tests comparing log_{10} inactivation of MS2 and phi6 for an expanded set of deposition solutions and treatment settings.



Figure S1. Experimental setup of 2a) a N95 respirator coupon attached to a coated metal rack with metal binder clip and 2b) the rack with a coupon placed in the temperature and humidity-controlled oven.



Figure S2. Inactivation of bacteriophages at 82°C and 13% in MHV media and IAV media. Independent experimental replicates (N = 2) are shown for each virus at each condition.



Figure S3. Virus inactivation as a function of absolute humidity for a) MS2 bacteriophage, b) phi6 bacteriophage, c) IAV, and d) MHV. Open faded symbols indicate virus inactivation beyond assay detection limits. Independent experimental replicates (N = 2) are shown for each virus at each condition.